Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503084 | 0.92 | DGAT1 (0.43) | DGAT1USP30WNT3A | |
| SCHEMBL6490517 | 0.89 | NQO2 (0.44) | DGAT1USP30NPC1RAB9AALDH1A1 | |
| SCHEMBL6500637 | 0.85 | TP53 (0.43) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL6491679 | 0.85 | USP30 (0.43) | DGAT1USP30 | |
| SCHEMBL6490896 | 0.85 | DGAT1 (0.40) | DGAT1USP30NPC1RAB9AWNT3A | |
| SCHEMBL6500752 | 0.85 | USP30 (0.52) | DGAT1USP30HDAC6 | |
| SCHEMBL6489240 | 0.84 | USP30 (0.43) | DGAT1USP30HDAC6 | |
| SCHEMBL6499660 | 0.84 | USP30 (0.43) | DGAT1USP30HDAC6 | |
| SCHEMBL6497610 | 0.83 | HDAC6 (0.47) | DGAT1USP30NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6497171 | 0.83 | HDAC1 (0.46) | DGAT1USP30NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | DGAT1 2495/4885USP30 3442/4885NPC1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.